453 related articles for article (PubMed ID: 16204693)
1. 5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine.
Correale P; Del Vecchio MT; Di Genova G; Savellini GG; La Placa M; Terrosi C; Vestri M; Urso R; Lemonnier F; Aquino A; Bonmassar E; Giorgi G; Francini G; Cusi MG
J Natl Cancer Inst; 2005 Oct; 97(19):1437-45. PubMed ID: 16204693
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs.
Correale P; Del Vecchio MT; La Placa M; Montagnani F; Di Genova G; Savellini GG; Terrosi C; Mannucci S; Giorgi G; Francini G; Cusi MG
J Immunother; 2008; 31(2):132-47. PubMed ID: 18481383
[TBL] [Abstract][Full Text] [Related]
3. In vitro generation of cytotoxic T lymphocytes against HLA-A2.1-restricted peptides derived from human thymidylate synthase.
Correale P; Sabatino M; Cusi MG; Micheli L; Nencini C; Pozzessere D; Petrioli R; Aquino A; De Vecchis L; Turriziani M; Prete SP; Sanguedolce R; Rausa L; Giorgi G; Francini G
J Chemother; 2001 Oct; 13(5):519-26. PubMed ID: 11760216
[TBL] [Abstract][Full Text] [Related]
4. The transfection of thymidylate synthase antisense suppresses oncogenic properties of a human colon cancer cell line and augments the antitumor effect of fluorouracil.
Matsuoka K; Tsukuda K; Suda M; Kobayashi K; Ota T; Okita A; Watanabe K; Suzuki E; Murakami M; Doihara H; Shimizu N
Int J Oncol; 2004 Jan; 24(1):217-22. PubMed ID: 14654960
[TBL] [Abstract][Full Text] [Related]
5. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
6. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide.
Correale P; Walmsley K; Zaremba S; Zhu M; Schlom J; Tsang KY
J Immunol; 1998 Sep; 161(6):3186-94. PubMed ID: 9743387
[TBL] [Abstract][Full Text] [Related]
7. More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells.
Dai S; Wan T; Wang B; Zhou X; Xiu F; Chen T; Wu Y; Cao X
Clin Cancer Res; 2005 Oct; 11(20):7554-63. PubMed ID: 16243831
[TBL] [Abstract][Full Text] [Related]
8. A potential important role for thymidylate synthetase inhibition on antitumor activity of fluoropyrimidine and raltitexed.
Kabeshima Y; Kubota T; Watanabe M; Saikawa Y; Nishibori H; Hasegawa H; Kitajima M
Anticancer Res; 2002; 22(6A):3245-52. PubMed ID: 12530071
[TBL] [Abstract][Full Text] [Related]
9. Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo.
Kase S; Kubota T; Watanabe M; Furukawa T; Tanino H; Ishibiki K; Teramoto T; Kitajima M
Anticancer Res; 1993; 13(2):369-73. PubMed ID: 8517649
[TBL] [Abstract][Full Text] [Related]
10. Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro.
Correale P; Aquino A; Giuliani A; Pellegrini M; Micheli L; Cusi MG; Nencini C; Petrioli R; Prete SP; De Vecchis L; Turriziani M; Giorgi G; Bonmassar E; Francini G
Int J Cancer; 2003 Apr; 104(4):437-45. PubMed ID: 12584740
[TBL] [Abstract][Full Text] [Related]
11. A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses.
Conforti A; Peruzzi D; Giannetti P; Biondo A; Ciliberto G; La Monica N; Aurisicchio L
J Immunother; 2009 Sep; 32(7):744-54. PubMed ID: 19561534
[TBL] [Abstract][Full Text] [Related]
12. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
[TBL] [Abstract][Full Text] [Related]
13. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K
Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913
[TBL] [Abstract][Full Text] [Related]
14. Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents.
Yawata A; Kim SR; Miyajima A; Kubo T; Ishida S; Saito Y; Nakajima Y; Katori N; Matsumoto Y; Fukuoka M; Ohno Y; Ozawa S; Sawada J
Cancer Chemother Pharmacol; 2005 Nov; 56(5):465-72. PubMed ID: 15918040
[TBL] [Abstract][Full Text] [Related]
15. Cell cycle regulation of the G0/G1 transition in 5-fluorouracil-sensitive and -resistant human colon cancer cell lines.
McGinn CJ; Pestalozzi BC; Drake JC; Glennon MC; Kunugi K; Otterson G; Allegra CJ; Johnston PG; Kinsella TJ
Cancer J; 2000; 6(4):234-42. PubMed ID: 11038143
[TBL] [Abstract][Full Text] [Related]
16. [The correlation between thymidylate synthase expression and cytotoxicity of 5-fluorouracil in human cancer cell lines: study using polyclonal antibody against recombinant human thymidylate synthase].
Okabe H; Tsujimoto H; Fukushima M
Gan To Kagaku Ryoho; 1997 Apr; 24(6):705-12. PubMed ID: 9126308
[TBL] [Abstract][Full Text] [Related]
17. Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.
Kadota K; Huang CL; Liu D; Yokomise H; Haba R; Wada H
Int J Oncol; 2011 Feb; 38(2):355-63. PubMed ID: 21174056
[TBL] [Abstract][Full Text] [Related]
18. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.
Eguchi J; Hatano M; Nishimura F; Zhu X; Dusak JE; Sato H; Pollack IF; Storkus WJ; Okada H
Cancer Res; 2006 Jun; 66(11):5883-91. PubMed ID: 16740728
[TBL] [Abstract][Full Text] [Related]
19. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
Gritzapis AD; Mahaira LG; Perez SA; Cacoullos NT; Papamichail M; Baxevanis CN
Cancer Res; 2006 May; 66(10):5452-60. PubMed ID: 16707474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
